BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CariCord

Celularity Acquires CariCord, Adds Biosourcing Assets, Establishes Relationship with ClinImmune Labs

September 4, 2018 By Cade Hildreth (CEO) Leave a Comment

Celularity acquires Caricord

WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]

Filed Under: Cord Blood, Press Releases Tagged With: CariCord, Celularity, cord blood

CariCord Partners with Singapore’s CellResearch Corp to Join “Global Cord Registry” & Launch Cord Tissue Storage in U.S.

November 30, 2016 By Cade Hildreth (CEO) Leave a Comment

CariCord Cord Tissue Storage

CariCord - Cord Blood BankSingapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.

As stated in the November 30, 2016, press release:

“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).

This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”

CellResearch CorporationThis license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.

To learn more, read the full press release from CellResearch Corporation.

Filed Under: Cord Blood, MSCs, Press Releases, Stem Cell News, Stem Cells Tagged With: CariCord, CellResearch Corp, Clinimmune, cord tissue

Major Industry Alliance: CariCord and ClinImmune Labs Partner with International Space Medicine Consortium

May 12, 2015 By Cade Hildreth (CEO) Leave a Comment

CariCord and ISMC Announce Partnership

AUTHOR: Authored by Wendy Roberts, PR Director of Orca Communications Unlimited, LLC.

COMMENT BY BIOINFORMANT:  Leading global players within cord blood industry frequently attain their industry dominance through industry collaborations.  In the announcement below, released May 11, 2015, CariCord and ClinImmune Labs announce a major industry partnership that will study the survivability of umbilical cord blood stem cells under micro gravity (Micro-G) simulation.

CariCord, a private stem cell bank at the University of Colorado, is a FDA-licensed cord blood manufacturer that has processed nearly 9,000 cord blood units and released 700+ for transplantation across 150+ hospitals worldwide.  While CariCord is not as substantial in size as other key players within the U.S. cord blood industry (most notably Cord Blood Registry, ViaCord, and Cryo-Cell, respectively) the company is positioning itself for increased visibility and growth through this strategic collaboration. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: alliances, CariCord, Clinimmune, cord blood banking, hematopoietic stem cells, ISMC, market news, partnership

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.